Evidence map›Paper›PMID 38405342›Full record

ArticleJournal of Alzheimer's disease reports2024

Validity and Reliability Study of Online Cognitive Tracking Software (BEYNEX).

Nilgün Çınar, Sude Aslan Kendirli, Miruna Florentina Ateş, Ezgi Yakupoğlu, Ebru Akbuğa, Naci Emre Bolu, Fenise Selin Karalı, Tuğba Okluoğlu, Nazlı Gamze Bülbül, Elif Bayindir and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Nilgün ÇınarDepartment of Neurology, Faculty of Medicine, Maltepe University, Istanbul, Turkey.
Sude Aslan KendirliDepartment of Neurology, Faculty of Medicine, Maltepe University, Istanbul, Turkey.
Miruna Florentina AteşDepartment of Neurology, Faculty of Medicine, Maltepe University, Istanbul, Turkey.
Ezgi YakupoğluDepartment of Neurology, Acıbadem Altunizade Hospitals, Istanbul, Turkey.
Ebru AkbuğaDepartment of Physiotherapy and Rehabilitation, Yeditepe University, Istanbul, Turkey.
Naci Emre BoluDepartment of Neurology, Faculty of Medicine, Maltepe University, Istanbul, Turkey.
Fenise Selin KaralıDepartment of Speech and Language Therapy English, Biruni University, Istanbul, Turkey.
Tuğba OkluoğluDepartment of Neurology, Istanbul Eğitim Araştırma Hastanesi, Istanbul, Turkey.
Nazlı Gamze BülbülDepartment of Neurology, Haydarpaşa Sultan Abdülhamid Han Eğitim ve Araştırma Hastanesi, Istanbul, Turkey.
Elif BayindirBEYNEX Technologies OÜ, Tallinn, Estonia.
Kamil Tolga AtamBEYNEX Technologies OÜ, Tallinn, Estonia.
Enis HisarlıBEYNEX Technologies OÜ, Tallinn, Estonia.
Sarp AkgönülBEYNEX Technologies OÜ, Tallinn, Estonia.
Oğulcan BagatırBEYNEX Technologies OÜ, Tallinn, Estonia.
Emre SahinerBEYNEX Technologies OÜ, Tallinn, Estonia.
Bora OrgenBoğaziçi University, Istanbul, Turkey.
Türker Ahmet Hasan SahinerDepartment of Neurology, Memorial Hospitals, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Detecting cognitive impairment such as Alzheimer's disease early and tracking it over time is essential for individuals at risk of cognitive decline. Objective: This research aimed to validate the Beynex app's gamified assessment tests and the Beynex Performance Index (BPI) score, which monitor cognitive performance across seven categories, considering age and education data. Methods: Beynex test cut-off scores of participants ( Results: Beynex categorization scores showed a moderate agreement with MoCA ratings (weighted Cohen's Kappa = 0.48; 95% CI: 0.38-0.60). Calculated Cronbach's Alpha indicates good internal consistency. Test-retest reliability analysis using a linear regression line fitted to results yielded R Discussion: Beynex's ability to reliably detect and track cognitive impairment could significantly impact public health, early intervention strategies and improve patient outcomes.

Indexed as

Alzheimer’s diseaseBeynexcognitive declinecognitive impairmentcognitive screening testcomputerized cognitive trackingdementiaearly detectionmemoryMontreal Cognitive Assessment

Identifiers

PMID38405342
PMCPMC10894610

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.